64
Medeon Biodesign, Inc.
6499.TWO · TWO
$80.60 +1.38% (+$1.10)
1M +13.04%
Market Cap $7.81B
P/E Ratio -
Div. Yield -
ROE 46.17%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
14 /100
Expensive P/S 18.25x
P/B 5.75x
P/E N/A
Growth
58 /100
Stable Rev. growth 12.03%
Book val. growth 25.70%
EPS growth N/A
Profitability
1 /100
Weak Gross margin 9.16%
Net margin 137.81%
Op. margin 144.73%
Quality
3 /100
Poor ROIC 39.18%
ROE 46.17%
ROA 35.13%
Debt
69 /100
Low Debt/Equity 0.12x
Current ratio 8.21x
Int. coverage -208.23x
Stability
26 /100
Unstable Beta 0.63x
Rev. volatility 46.53%
EPS volatility 117.54%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 6499.TWO
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Yu Te Chang
Employees
1,496
Headquarters
Taipei
Upcoming events
29 OCT
Earnings
Upcoming earnings report